AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol (January 17, 2006). doi:10.1152/ajprenal.00485.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/6/F1453    most recent
00485.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zager, R. A.
Right arrow Articles by Abrass, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zager, R. A.
Right arrow Articles by Abrass, C. K.
Submitted on December 6, 2005
Accepted on January 10, 2006

Levosimendan Protects Against Experimental Endotoxemic Acute Renal Failure

Richard A. Zager1*, Ali C. Johnson2, Steve Lund2, Sherry Y. Hanson2, and Christine K. Abrass3

1 Department of Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA
2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA
3 Veterans Administration Puget Sound Health Care System, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA

* To whom correspondence should be addressed. E-mail: dzager{at}fhcrc.org.

Background: Endotoxemia induces a hemodynamic form of acute renal failure (ARF) [renal vasoconstriction ± reduced glomerular ultrafilitration coefficient, Kf; minimal / no histologic damage]. This study tested whether levosimendan (LS), a KATP channel opener with cardiac ionotropic and possible anti-inflammatory properties, might have utility in combating this form of ARF. Methods: CD-1 mice were injected with lipopolysaccharide (LPS) ± LS. LS effects on LPS- induced systemic inflammation (plasma TNF-{alpha} / MCP-1; cardio-renal mRNAs), plasma nitric oxide (NO) levels, and azotemia were assessed. Because KATP channel opening has been reported to mediate hypoxic tubular injury, possible adverse LS effects on ischemic ARF, and on ATP depletion- injury, were sought (in HK-2 cells and isolated mouse proximal tubules). The impacts of diazoxide (another KATP channel agonist) and glibenclamide (a channel antagonist) on hypoxic tubular injury were also assessed. Finally, the ability of LS to alter rat mesangial cell (MC) contraction in response to angiotensin II (AII; elevated in sepsis) was tested. Results: LS conferred almost complete protection against LPS-induced ARF. This occurred without any apparent reduction in the LPS- induced inflammatory response. Neither LS nor diazoxide altered ATP depletion- mediated tubule injury (in vivo or in vitro). Conversely, glibenclamide induced a marked and direct cytotoxic effect. LS completely blocked AII- induced MC contraction, an action likely to increase Kf. Conclusions: 1) LS can confer marked protection against LPS- induced ARF; 2) This likely stems from its vasoactive properties, rather than from reductions in LPS induced inflammation; and 3) KATP channel agonists (but not antagonists) appear to be devoid of toxic proximal tubular cell effects. This suggests that LS, and other KATP channel agonists, have a margin of safety if employed in situations (e.g., sepsis syndrome, heart failure) in which severe renal vasoconstriction might lead to ischemic ARF




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
D. Cunha-Goncalves, V. Perez-de-Sa, A. Larsson, J. Thorne, and S. Blomquist
Inotropic Support During Experimental Endotoxemic Shock: Part II. A Comparison of Levosimendan with Dobutamine
Anesth. Analg., November 1, 2009; 109(5): 1576 - 1583.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. Nakamura, Y. Komagiri, T. Kojo, and M. Kubokawa
Delayed and acute effects of interferon-{gamma} on activity of an inwardly rectifying K+ channel in cultured human proximal tubule cells
Am J Physiol Renal Physiol, January 1, 2009; 296(1): F46 - F53.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
M. S. Nieminen, J. G.F. Cleland, J. Eha, Y. Belenkov, M. Kivikko, P. Poder, and T. Sarapohja
Oral levosimendan in patients with severe chronic heart failure--The PERSIST study
Eur J Heart Fail, December 1, 2008; 10(12): 1246 - 1254.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Z. Sun, X. Zhang, K. Ito, Y. Li, R. A. Montgomery, S. Tachibana, and G. M. Williams
Amelioration of oxidative mitochondrial DNA damage and deletion after renal ischemic injury by the KATP channel opener diazoxide
Am J Physiol Renal Physiol, March 1, 2008; 294(3): F491 - F498.
[Abstract] [Full Text] [PDF]


Home page
pdiHome page
A. G. Zenovich and D. A. Taylor
CELL THERAPY IN KIDNEY DISEASE: CAUTIOUS OPTIMISM... BUT OPTIMISM NONETHELESS
Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S94 - S103.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
L. Wu, M. M. Tiwari, K. J. Messer, J. H. Holthoff, N. Gokden, R. W. Brock, and P. R. Mayeux
Peritubular capillary dysfunction and renal tubular epithelial cell stress following lipopolysaccharide administration in mice
Am J Physiol Renal Physiol, January 1, 2007; 292(1): F261 - F268.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.